RT Journal Article
SR Electronic
T1 Bacterial superinfection pneumonia in SARS-CoV-2 respiratory failure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.12.20248588
DO 10.1101/2021.01.12.20248588
A1 Pickens, Chiagozie O.
A1 Gao, Catherine A.
A1 Cuttica, Michael
A1 Smith, Sean B.
A1 Pesce, Lorenzo
A1 Grant, Rogan
A1 Kang, Mengjia
A1 Morales-Nebreda, Luisa
A1 Bavishi, Avni A.
A1 Arnold, Jason
A1 Pawlowski, Anna
A1 Qi, Chao
A1 Budinger, GR Scott
A1 Singer, Benjamin D.
A1 Wunderink, Richard G.
A1 for the NU COVID Investigators
YR 2021
UL http://medrxiv.org/content/early/2021/01/15/2021.01.12.20248588.abstract
AB Background Severe community-acquired pneumonia secondary to SARS-CoV-2 is a leading cause of death. Current guidelines recommend patients with SARS-CoV-2 pneumonia receive empirical antibiotic therapy for suspected bacterial superinfection, but little evidence supports these recommendations.Methods We obtained bronchoscopic bronchoalveolar lavage (BAL) samples from patients with SARS-CoV-2 pneumonia requiring mechanical ventilation. We analyzed BAL samples with multiplex PCR and quantitative culture to determine the prevalence of superinfecting pathogens at the time of intubation and identify episodes of ventilator-associated pneumonia (VAP) over the course of mechanical ventilation. We compared antibiotic use with guideline-recommended care.Results The 179 ventilated patients with severe SARS-CoV-2 pneumonia discharged from our hospital by June 30, 2020 were analyzed. 162 (90.5%) patients had at least one BAL procedure; 133 (74.3%) within 48 hours after intubation and 112 (62.6%) had at least one subsequent BAL during their hospitalization. A superinfecting pathogen was identified within 48 hours of intubation in 28/133 (21%) patients, most commonly methicillin-sensitive Staphylococcus aureus or Streptococcus species (21/28, 75%). BAL-based treatment reduced antibiotic use compared with guideline-recommended care. 72 patients (44.4%) developed at least one VAP episode. Only 15/72 (20.8%) of initial VAPs were attributable to multidrug-resistant pathogens. The incidence rate of VAP was 45.2/1000 ventilator days.Conclusions With use of sensitive diagnostic tools, bacterial superinfection at the time of intubation is infrequent in patients with severe SARS-CoV-2 pneumonia. Treatment based on current guidelines would result in substantial antibiotic overuse. The incidence rate of VAP in ventilated patients with SARS-CoV-2 pneumonia are higher than historically reported.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Institutes of Health, National Institute of Allergy and Infectious Diseases (AI135964), National Heart Lung, and Blood Institute (HL128867, HL149883, HL147575), National Institute on Aging (AG049665, T32AG020506), National Library of Medicine (LM13337); NUCATS COVID-19 Rapid Response Grant; Chest FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Northwestern University Institutional Review Board (STU00212283) approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.